Tenax Therapeutics (NASDAQ:TENX) Earns Sell Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of Tenax Therapeutics (NASDAQ:TENX) in a report published on Sunday morning. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.

A number of other research firms also recently weighed in on TENX. William Blair restated an “outperform” rating on shares of Tenax Therapeutics in a research note on Monday, March 10th. Leerink Partners set a $20.00 price objective on Tenax Therapeutics in a report on Monday, March 10th. One research analyst has rated the stock with a sell rating, three have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $18.00.

Tenax Therapeutics Trading Up 3.5 %

Shares of TENX opened at $5.95 on Friday. The stock has a market capitalization of $23.62 million, a price-to-earnings ratio of -1.12 and a beta of 1.88. Tenax Therapeutics has a 12 month low of $2.77 and a 12 month high of $7.89. The firm has a fifty day simple moving average of $6.39 and a 200 day simple moving average of $5.56.

Tenax Therapeutics (NASDAQ:TENX) last posted its quarterly earnings data on Tuesday, March 25th. The specialty pharmaceutical company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.34. As a group, research analysts predict that Tenax Therapeutics will post -0.88 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Tenax Therapeutics

Institutional investors have recently bought and sold shares of the business. Janus Henderson Group PLC bought a new position in shares of Tenax Therapeutics during the 4th quarter worth approximately $1,026,000. Millennium Management LLC acquired a new stake in Tenax Therapeutics during the 4th quarter valued at $166,000. Geode Capital Management LLC boosted its position in Tenax Therapeutics by 32.4% during the fourth quarter. Geode Capital Management LLC now owns 24,354 shares of the specialty pharmaceutical company’s stock worth $151,000 after purchasing an additional 5,964 shares during the period. Finally, Two Sigma Investments LP acquired a new position in shares of Tenax Therapeutics in the fourth quarter valued at $84,000. Institutional investors and hedge funds own 1.67% of the company’s stock.

About Tenax Therapeutics

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.